Skip to main content
OpenTrials
Completed

NCT Number: NCT03176303

Study Using the SpinalStim Device Following Lumbar Fusion Surgery

This study examines the effect of adjunctive use of the SpinalStim bone growth stimulator on lumbar fusion rate in high risk subjects who have had lumbar fusion surgery. All participants will wear the bone growth stimulator for a minimum of 2 hours/day for 6 months.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

ClinTech Center for Spine Health

Johnstown, Colorado, 80534, United States

About this study

The purpose of this post market prospective study is to examine the effect of the adjunctive use of the Orthofix SpinalStim™ device on lumbar fusion rate in high risk subjects who have undergone lumbar fusion surgery. High risk subjects are those who are currently using nicotine, who are having a multi-level fusion, who have had a prior failed fusion at any lumbar level, who are diabetic or who are osteoporotic. Because this is a post market prospective study, subjects who are enrolled in this study will be identified by the Investigator as needing lumbar fusion surgery and asked if they would like to participate in a study looking at the efficacy of lumbar fusion with adjunctive use of the SpinalStim bone growth simulator. The type of lumbar fusion surgery performed (lateral lumbar interbody fusion [XLIF], posterior lumbar interbody fusion [PLIF], anterior lumbar interbody fusion [ALIF], posterolateral fusion) is up to the Investigator; the subjects in the study must be agreeable to using the bone growth stimulator daily for 6 months post surgery.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Male or female, ≥ 18 years of age at the time of Informed Consent
  • Requires a lumbar fusion surgery within 30 days of signing Informed Consent.

a. Surgical approach is according to physician's discretion.

  • Subject has one or more risk factors:
  • Is currently using nicotine
  • multi-level lumbar fusion surgery planned
  • Prior failed fusion at any lumbar level
  • Subject reported diabetes
  • Subject reported osteoporosis
  • Body mass index ≤ 45 kg/m2 at the time of consent.
  • Must have reliable access to an iPhone or an iPad with Wi-Fi access for downloading the free device-specific app (iPhone 5S or higher, iPad, iPad Pro, iPad mini or iTouch using iOS v9.3 or later). When the android version of the mobile app for the SpinalStim becomes available (estimated to be Dec. 2017), subjects who have reliable access to devices using android operating systems will be eligible for study inclusion.
  • Able and willing to complete electronic questionnaires and able to read and understand study instructions in English
  • Able and willing to comply with the study plan and able to understand and sign the study-specific ICF.

Exclusion criteria

  • Scoliosis greater than 30 degrees
  • Current alcoholism or drug abuse, and/or any known current addiction to pain medications or medical marijuana
  • Any active malignancy or prior history of malignancy within last 5 years prior to fusion (except basal cell carcinoma of the skin).
  • Any clinically significant finding that places the subject at health risk, impacts the study, or affects completion of the study, in the opinion of the Investigator
  • Any psychiatric illness that prevents subject from completing the assessments accurately, in the opinion of the Investigator
  • Prisoners.

Treatment and study plan

SpinalStim

Device

PEMF osteogenesis stimulator

Primary outcomes

  1. fusion rate

    Time frame: 12 months

    number of subjects with fused lumbar vertebrae, determined by X-rays and CT scans

Secondary outcomes

  1. Device compliance

    Time frame: 6 months

    actual minutes per day device was used compared with prescribed treatment time

  2. revision rate

    Time frame: 12 months

    how many subjects had to be reoperated (revised) at the same level(s) during the course of the study

  3. SF-36

    Time frame: 12 months

    used to assess the effect of PEMF treatment on subject quality of life

  4. Oswestry Disability Index

    Time frame: 12 months

    used to examine the effect of PEMF treatment on subject disability

  5. VAS pain

    Time frame: 12 months

    used to assess the effect of PEMF treatment on reduction of pain

  6. EQ-5D

    Time frame: 12 months

    used to assess the effect of PEMF treatment on quality of life and economic impact

Sponsors and collaborators

Lead sponsor

Orthofix Inc.

Industry

Registry information

Official study title

A Multi-Center, Open-Label, Prospective Study of SpinalStim™ (MOP-SS) as Adjunctive Care Following Lumbar Fusion Surgery

Important dates

Study start
2017
Primary completion
2021
Study completion
2021
First posted
Jun 5, 2017
Registry last updated
Sep 16, 2022

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.